STOCK TITAN

ABVC BioPharma Inc - ABVC STOCK NEWS

Welcome to our dedicated news page for ABVC BioPharma (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on ABVC BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ABVC BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ABVC BioPharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
72.58%
Tags
clinical trial fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.37%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.84%
Tags
clinical trial
ABVC BioPharma Inc

Nasdaq:ABVC

ABVC Rankings

ABVC Stock Data

12.67M
6.80M
26.97%
2.43%
1.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Fremont

About ABVC

american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br